Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERU-111 for the Treatment of SARS-CoV-2 in Patients at High Risk for ARDS
NCT04842747Phase 3Completed
- Sponsor
- Veru Inc.
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of sabizabulin in Coronavirus Disease 2019 (COVID-19), sponsored by Veru Inc.. Started May 2021; status: completed.
02
Drugs
sabizabulin
03
Conditions
Coronavirus Disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04842747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842747.